Form 4: ADC Therapeutics SA: Chief Legal Officer Acquires 220,000 Common Shares

Peter J. Graham, Chief Legal Officer of ADC Therapeutics SA, acquired 220,000 common shares on February 13, 2025, at a price of $1.61 per share.

Summary

• Peter J. Graham, the Chief Legal Officer of ADC Therapeutics SA, acquired 220,000 common shares on February 13, 2025.
• The shares were acquired at a price of $1.61 per share.
• This acquisition increases Graham's direct ownership to 408,542 common shares.
• The acquisition is related to the settlement of a restricted share unit award.
• The restricted share units vest in three equal installments annually, starting on February 13, 2026, contingent upon continued service.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine disclosure of share acquisition by an officer, which can be seen as a positive sign of confidence, but it's not a major event.

Positives

• The acquisition of shares by a company officer can be seen as a positive sign, indicating confidence in the company's future prospects.

Future Outlook

The restricted share units will continue to vest annually over the next two years, contingent upon continued service.

Industry Context

Form 4 filings are standard practice and provide transparency into the transactions of company insiders, allowing investors to track ownership changes and potential alignment of interests.

Key Dates

Keywords

ADC Therapeutics SA, Peter J. Graham, Chief Legal Officer, Common Shares, Acquisition, Restricted Share Units, Beneficial Ownership, ADCT